Two new vaccines could help stop respiratory virus infections in older adults

Embargoed until: Publicly released: 2023-02-16 09:00

Australia; International

Trials of two new vaccines against the respiratory syncytial virus (RSV), an important cause of respiratory infection and death in older adults, have shown positive results in clinical trials. One large clinical trial, conducted across 17 countries including Australia, showed a single dose of vaccine had an efficacy of 94.1% against severe RSV-related lower respiratory tract disease and 71.7% against any RSV-related acute respiratory infection. A second smaller trial for a different vaccine showed an efficacy of between 80% and 69.8% depending on the disease symptoms. There is currently no licensed vaccine against RSV infection.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page Paper 1 - Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Research Massachusetts Medical Society, Web page Paper 2 - Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: GlaxoSmithKline, Janssen Vaccines and Prevention

Funder: Paper 1: Supported by GlaxoSmithKline Biologicals. Paper2: Funded by Janssen Vaccines and Prevention

Media Contact/s

Contact details are only visible to registered journalists.